# OnCo record letetresgene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/letetresgene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "letetresgene-autoleucel" ;
  schema:name "Letetresgene autoleucel"@en ;
  schema:description "Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026."@en ;
  schema:url <https://onco.cc/drugs/letetresgene-autoleucel/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03967223> ;
  onco:status "phase-2" ;
  onco:modality "TCR-T (NY-ESO-1)" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/tcr-t/> ;
  onco:targets <https://onco.cc/targets/hla-a/> ;
  onco:companies <https://onco.cc/companies/us-worldmeds/> ;
  onco:terms <https://onco.cc/terms/crs/> ;
  onco:trials <https://onco.cc/trials/ignyte-eso/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-spearhead-1-lancet-2024/> .